205 related articles for article (PubMed ID: 14708970)
1. Effects of bosentan on cellular processes involved in pulmonary arterial hypertension: do they explain the long-term benefit?
Clozel M
Ann Med; 2003; 35(8):605-13. PubMed ID: 14708970
[TBL] [Abstract][Full Text] [Related]
2. Bosentan: a dual endothelin receptor antagonist.
Rubin LJ; Roux S
Expert Opin Investig Drugs; 2002 Jul; 11(7):991-1002. PubMed ID: 12084009
[TBL] [Abstract][Full Text] [Related]
3. Role of iloprost and bosentan in pulmonary arterial hypertension.
Saleh JA
Niger J Med; 2008; 17(1):13-9. PubMed ID: 18390125
[TBL] [Abstract][Full Text] [Related]
4. Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence.
Provencher S; Sitbon O; Simonneau G
Expert Opin Pharmacother; 2005 Jul; 6(8):1337-48. PubMed ID: 16013984
[TBL] [Abstract][Full Text] [Related]
5. Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension.
Kim H; Yung GL; Marsh JJ; Konopka RG; Pedersen CA; Chiles PG; Morris TA; Channick RN
Eur Respir J; 2000 Apr; 15(4):640-8. PubMed ID: 10780753
[TBL] [Abstract][Full Text] [Related]
6. Review on bosentan, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
Serasli E; Michaelidis V; Kosmas A; Antoniadou M; Tsara V
Recent Pat Cardiovasc Drug Discov; 2010 Nov; 5(3):184-95. PubMed ID: 20874675
[TBL] [Abstract][Full Text] [Related]
7. Bosentan prevents hypoxia-reoxygenation-induced pulmonary hypertension and improves pulmonary function.
Pearl JM; Wellmann SA; McNamara JL; Lombardi JP; Wagner CJ; Raake JL; Nelson DP
Ann Thorac Surg; 1999 Nov; 68(5):1714-21; discussion 1721-2. PubMed ID: 10585047
[TBL] [Abstract][Full Text] [Related]
8. Bosentan.
Chin K; Channick R
Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):175-82. PubMed ID: 15151466
[TBL] [Abstract][Full Text] [Related]
9. Acute hemodynamic effects of single oral dose of bosentan in patients with pulmonary arterial hypertension related to congenital heart disease.
Ajami G; Ahmadipour M; Amoozgar H; Bourzoee M; Cheriki S; Shakiba AM; Edraki MR
Congenit Heart Dis; 2014; 9(4):343-8. PubMed ID: 25247216
[TBL] [Abstract][Full Text] [Related]
10. Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension.
Rondelet B; Kerbaul F; Motte S; van Beneden R; Remmelink M; Brimioulle S; McEntee K; Wauthy P; Salmon I; Ketelslegers JM; Naeije R
Circulation; 2003 Mar; 107(9):1329-35. PubMed ID: 12628956
[TBL] [Abstract][Full Text] [Related]
11. Current status of bosentan for treatment of pulmonary hypertension.
Raja SG; Dreyfus GD
Ann Card Anaesth; 2008; 11(1):6-14. PubMed ID: 18182753
[TBL] [Abstract][Full Text] [Related]
12. Treatment with bosentan in a patient with thalassemia intermedia and pulmonary arterial hypertension.
Anthi A; Tsangaris I; Hamodraka ES; Lekakis J; Armaganidis A; Orfanos SE
Blood; 2012 Aug; 120(7):1531-2. PubMed ID: 22899478
[No Abstract] [Full Text] [Related]
13. Synergistic therapeutic effects of 2-methoxyestradiol with either sildenafil or bosentan on amelioration of monocrotaline-induced pulmonary hypertension and vascular remodeling.
Tofovic SP; Jones TJ; Bilan VP; Jackson EK; Petrusevska G
J Cardiovasc Pharmacol; 2010 Nov; 56(5):475-83. PubMed ID: 20881615
[TBL] [Abstract][Full Text] [Related]
14. Bosentan therapy for pulmonary arterial hypertension.
Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
[TBL] [Abstract][Full Text] [Related]
15. Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment.
Hall SM; Davie N; Klein N; Haworth SG
Eur Respir J; 2011 Oct; 38(4):851-60. PubMed ID: 21406517
[TBL] [Abstract][Full Text] [Related]
16. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis.
Sfikakis PP; Papamichael C; Stamatelopoulos KS; Tousoulis D; Fragiadaki KG; Katsichti P; Stefanadis C; Mavrikakis M
Arthritis Rheum; 2007 Jun; 56(6):1985-93. PubMed ID: 17530638
[TBL] [Abstract][Full Text] [Related]
17. Bosentan for chronic thromboembolic pulmonary hypertension.
Confalonieri M; Kodric M; Longo C; Vassallo FG
Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1503-12. PubMed ID: 19954311
[TBL] [Abstract][Full Text] [Related]
18. Improvement of bleomycin-induced pulmonary hypertension and pulmonary fibrosis by the endothelin receptor antagonist Bosentan.
Schroll S; Arzt M; Sebah D; Nüchterlein M; Blumberg F; Pfeifer M
Respir Physiol Neurobiol; 2010 Jan; 170(1):32-6. PubMed ID: 19931426
[TBL] [Abstract][Full Text] [Related]
19. Endothelin and endothelin antagonists in hypertension.
Schiffrin EL
J Hypertens; 1998 Dec; 16(12 Pt 2):1891-5. PubMed ID: 9886874
[TBL] [Abstract][Full Text] [Related]
20. Acute pulmonary hypertension after cardiopulmonary bypass in pig: the role of endogenous endothelin.
Carteaux JP; Roux S; Siaghy M; Schjöth B; Dolofon P; Bechamps Y; Mertes PM; Villemot JP
Eur J Cardiothorac Surg; 1999 Mar; 15(3):346-52. PubMed ID: 10333034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
